What biomarker testing is recommended for locally advanced Pancreatic Cancer

Biomarker Testing for Locally Advanced Pancreatic Cancer

Based on current clinical guidelines, here's what's recommended for biomarker testing in locally advanced pancreatic cancer:

What Testing Is Recommended

According to the NCCN Guidelines for Pancreatic Adenocarcinoma (2025), tumor/somatic molecular profiling is recommended for patients with locally advanced disease who are candidates for anti-cancer therapy. This testing should ideally use next-generation sequencing (NGS), which is a comprehensive genetic test that reads through your tumor's DNA to identify specific mutations and alterations.

Preferred Testing Approach:

• Tumor tissue is preferred for testing (obtained through biopsy)
• Cell-free DNA testing (a blood test) can be considered if tumor tissue testing isn't feasible
• RNA sequencing is preferred when looking for gene fusions, since fusions are detected better this way

What Specific Biomarkers Are Tested For

The NCCN Guidelines recommend looking for these clinically actionable alterations:

Gene Fusions:

• ALK, NRG1, NTRK, ROS1, FGFR2, and RET fusions

Gene Mutations:

• BRAF mutations
• BRCA1/BRCA2 mutations
• KRAS mutations
• PALB2 mutations

Gene Amplifications:

• HER2 amplifications

DNA Repair Deficiencies:

• Microsatellite instability (MSI)
• Mismatch repair deficiency (dMMR)
• Tumor mutational burden (TMB)

Protein Expression:

• HER2 overexpression (tested via immunohistochemistry or FISH)

Why This Matters for Treatment

According to the NCCN Guidelines, identifying these biomarkers is important because different mutations respond to different targeted therapies. For example:

• BRCA1/BRCA2 or PALB2 mutations may make you eligible for PARP inhibitors (like rucaparib/Rubraca)
• BRAF V600 mutations may respond to dabrafenib (Tafinlar) plus trametinib (Mekinist)
• NTRK fusions may respond to entrectinib (Rozlytrek) or larotrectinib (Vitrakvi)
• RET fusions may respond to selpercatinib (Retevmo)
• MSI or dMMR may respond to immunotherapy like pembrolizumab (Keytruda) or dostarlimab (Jemperli)

Additional Testing Recommended

Beyond molecular profiling, the NCCN Guidelines also recommend:

• Genetic testing for inherited mutations using comprehensive gene panels to check if you carry hereditary cancer risk genes (BRCA1, BRCA2, PALB2, ATM, CDKN2A, MLH1, MSH2, MSH6, PMS2, STK11, TP53)
• Genetic counseling if you test positive for any pathogenic mutations

Questions to Ask Your Oncologist

1. "Has molecular profiling been done on my tumor tissue? Can I see the report?" (This is important to keep a copy for yourself and any second opinions)

2. "What specific biomarkers were tested for, and what were the results?"

3. "Based on my biomarker results, am I eligible for any targeted therapies or clinical trials?"

4. "Should I have genetic testing done to check for inherited mutations?"

5. "If tissue testing wasn't possible, would a blood-based (cell-free DNA) test be appropriate for me?"

Important Context

According to Dr. [removed] O'Reilly's expert guidance on pancreatic cancer treatment, you should receive "point of care" genetic testing (both hereditary and tumor testing) at your first meeting with your oncology team, ideally accompanied by educational materials explaining the tests and results. The pace of treatment advances in pancreatic cancer is accelerating, and biomarker-guided treatment selection is becoming increasingly important for identifying which therapies may work best for your specific cancer.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.